NDRA
Live chart
What they do
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease.
For information only · Important disclosures
Grades vs sector
No sector grades for NDRA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (FY to 2020-12-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta -0.08 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-3.04 vs trailing $-6.26. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score -19.2 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2020 | $0 | $-11.7M | $-10.8M |
| 2019 | $0 | – | – |
| 2018 | $6.2K | – | – |
| 2017 | $351.6K | – | – |
| 2016 | $515.6K | – | – |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-14 | -0.84 | -1.17 | -39.4% |
| 2026-05-15 | -1.23 | -1.09 | +11.4% |
| 2026-03-31 | -1.23 | -2.23 | -81.7% |
| 2025-11-14 | -1.95 | -2.10 | -7.7% |
| 2025-08-14 | -2.27 | -1.71 | +24.7% |
| 2025-05-15 | -3.91 | -1.86 | +52.4% |
| 2025-03-31 | -4.10 | 25.20 | +714.6% |
| 2024-11-15 | -62.30 | -9.54 | +84.7% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Analyst actions
PT $25
PT $30
PT $38
PT $46
PT $50
PT $8
Stats refreshed 2026-10-21 12:16:16 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026